Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

133 results about "Diacylglycerol Acyltransferase" patented technology

Modulation of diacylglycerol acyltransferase 2 expression

Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
Owner:IONIS PHARMA INC

Mortierella alpina diacylglycerol acyltransferase for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms

An acyltransferase is provided, suitable for use in the manufacture of microbial oils enriched in omega fatty acids in oleaginous organisms. Specifically, the gene encoding diacylglycerol acyltransferase (DGAT2) has been isolated from Mortierella alpina. This gene encodes an enzyme that participates in the terminal step in oil biosynthesis in fungi and yeast and is expected to play a key role in altering the quantity of long-chain polyunsaturated fatty acids produced in oils of oleaginous organisms. Most desirably, the substrate specificity of the instant DGAT2 will be particularly useful to enable accumulation of long-chain PUFAs having chain lengths equal to or greater than C20 in oleaginous yeast, such as Yarrowia lipolytica.
Owner:DUPONT US HLDG LLC

Modulation of diacylglycerol acyltransferase 2 expression

Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
Owner:IONIS PHARMA INC

Modulation of diacylglycerol acyltransferase 2 expression

Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 2 are provided.
Owner:IONIS PHARMA INC

Modified photosynthetic microorganisms for producing triglycerides

This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacylglycerol acyltransferase, a phosphatidate phosphatase, and / or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and / or synthesizing triglycerides.
Owner:LUMEN BIOSCI INC

Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease

Compositions for the prevention and treatment of obesity, cardiovascular and coronary artery diseases are provided. The present invention provides compositions comprising at least one dibenzo-p-dioxine derivatives having inhibition ability against diacylglycerol acyltransferase (DGAT), and also provides the use of the compositions as a component of drugs or dietary supplements intended for the prevention and treatment of obesity, cardiovascular and coronary artery diseases. Since the compositions of the invention are nontoxic, allowing their chronic ingestion, easier and natural control of obesity and related diseases frequently found in obese people can be realized.
Owner:THE SKINNY DRINK

Mono-and diacylglycerol acyltransferases and methods of use thereof

InactiveUS20050106697A1Sugar derivativesPeptide/protein ingredientsMonoacylglycerol acyltransferaseDiglyceride acyltransferase
Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase and / or monoacylglycerol acyltransferase activity, as well as the polypeptide products encoded thereby, i.e., mammalian DGAT2α, MGAT1, or MGAT2 polypeptide products, and methods for producing the same, are provided. Also provided are: methods and compositions for modulating DGAT2α, MGAT1, or MGAT2 activity; DGAT2α, MGAT1, or MGAT2 transgenic cells, animals and plants, as well as methods for their preparation; and methods for making diglyceride, diglyceride compositions, triglycerides and triglyceride compositions, as well as the compositions produced by these methods. The subject methods and compositions find use in a variety of different applications, including research, medicine, agriculture and industry applications.
Owner:THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS

Acyltransferases for alteration of polyunsaturated fatty acids and oil content in oleaginous yeasts

Two acyltransferases are provided, suitable for use in the manufacture of microbial oils enriched in omega fatty acids in oleaginous yeast (e.g., Yarrowia lipolytica). Specifically, the genes encoding phophatidylcholine-diacylglycerol acyltransferase (PDAT) and diacylglycerol acyltransferase (DGAT2) have been isolated from Y. lipolytica. These genes encode enzymes that participate in the terminal step in oil biosynthesis in yeast. Each is expected to play a key role in altering the quantity of polyunsaturated fatty acids produced in oils of oleaginous yeasts.
Owner:EI DU PONT DE NEMOURS & CO

Diacylglycerol acyl transferase proteins

InactiveUS7135617B2Increase percentageIncreased DAGAT activitySugar derivativesPeptide/protein ingredientsDiseaseMortierella ramanniana
The invention provides diacylglycerol acyltransferase (DAGAT) proteins, wherein said proteins are active in the formation of triacylglycerol from fatty acyl and diacylglycerol substrates. In one aspect, Mortierella ramanniana DAGAT proteins have been isolated and have molecular weights of between approximately 36 and 37 kDa as measured by SDS-PAGE. The invention also provides novel DAGAT polynucleotide and polypeptide sequences and to methods of producing such polypeptides using recombinannt techniques. In addition, methods are provided for using such sequences to alter triacylglycerol levels in plants and to treat diseases associated with altered DAGAT activity or expression.
Owner:MONSANTO TECH LLC

Diacylglycerol acyltransferase 2 inhibitors

Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Owner:PFIZER INC

Diacylglycerol acyltransferase nucleic acid sequences and associated products

The present invention is directed to polypeptides and nucleic acid sequences related thereto, and methods to purify, obtain, and use such molecules in genetic engineering applications. More specifically, the present invention relates to polypeptides associated with the production of triacylglycerols in plants and fungi.
Owner:MONSANTO TECH LLC

Diacylglycerol acyl transferase proteins

InactiveUS7741532B2BacteriaPeptide/protein ingredientsMortierella ramannianaPolynucleotide
The invention provides diacylglycerol acyltransferase (DAGAT) proteins, wherein said proteins are active in the formation of triacylglycerol from fatty acyl and diacylglycerol substrates. In one aspect, Mortierella ramanniana DAGAT proteins have been isolated and have molecular weights of between approximately 36 and 37 kDa as measured by SDS-PAGE. The invention also provides novel DAGAT polynucleotide and polypeptide sequences and to methods of producing such polypeptides using recombinant techniques. In addition, methods are provided for using such sequences to alter triacylglycerol levels in plants and to treat diseases associated with altered DAGAT activity or expression.
Owner:MONSANTO TECH LLC

Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease

ActiveUS20190117709A1Inhibit progressEarly detectionOrganic active ingredientsDigestive systemFiberMonoacylglycerol acyltransferase
A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.
Owner:SEED HEALTH INC

Mono- and diacylglycerol acyltransferases and methods of use thereof

InactiveUS7045326B2BacteriaPeptide/protein ingredientsMonoacylglycerol acyltransferaseDiglyceride acyltransferase
Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase and / or monoacylglycerol acyltransferase activity, as well as the polypeptide products encoded thereby, i.e., mammalian DGAT2α and MGAT1 polypeptide products, and methods for producing the same, are provided. Also provided are: methods and compositions for modulating DGAT2α and MGAT1 activity; DGAT2α and MGAT1 transgenic cells, animals and plants, as well as methods for their preparation; and methods for making diglyceride, diglyceride compositions, triglycerides and triglyceride compositions, as well as the compositions produced by these methods. The subject methods and compositions find use in a variety of different applications, including research, medicine, agriculture and industry applications.
Owner:THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS

Deoxyribose nucleic acid (DNA) sequence for encoding parietchloris incise diacylglycerol acyltransferase and application thereof

ActiveCN102943081AHas the ability to synthesizeFungiBacteriaA-DNANucleotide sequencing
The invention relates to a separated deoxyribose nucleic acid (DNA) sequence. The DNA sequence comprises a nucleotide sequence (a) of SEQIDNO.1 or SEQIDNO.2; or a nucleotide sequence (b) complementary with the nucleotide sequence (a). The invention further provides a recombinant expression vector containing the nucleotide sequence, a genetic engineering host cell and application of the nucleotide sequence, the recombinant expression vector and the host cell for encoding the diacylglycerol acyltransferase or producing triacylglycerol. The DNA sequence has the advantages that a cDNA full-length sequence and a DNA full-length sequence of a parietchloris incise diacylglycerol acyltransferase gene are obtained by screening, encoded protein of the gene has a triacylglycerol synthesis capability by expression of the gene in a TAG synthesis defect strain H1246 of yeast, and conditions are created for utilizing the gene to achieve large-scale synthesis of triacylglycerol by genetic operation.
Owner:SHANGHAI OCEAN UNIV

Diacylglycerol acyltransferase (DGAT) assay

InactiveUS20020127627A1Reduce eliminate activityUseful biological activityCompound screeningApoptosis detectionAcetyltransferaseDrug biological activity
The present invention provides a method for measuring diacylglycerol acetyltransferase (DGAT) activity which utilizes a novel solvent system to reduce and / or eliminate the activities of related compounds. The present invention also discloses a method for determining whether a compound is useful for modulating DGAT biological activity. The method is capable of being utilized for mass screening of compounds as modulators of the biological activity of DGAT.
Owner:WARNER-LAMBERT CO

Modified photosynthetic microorganisms for producing triglycerides

This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacylglycerol acyltransferase, a phosphatidate phosphatase, and / or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and / or synthesizing triglycerides.
Owner:LUMEN BIOSCI INC

Diacylglycerol acyltransferase genes, proteins, and uses thereof

The present invention relates to diacylglycerol acyltransferase genes and proteins, and methods of their use. In particular, the invention describes genes and proteins that exhibit both long-chain acyltransferase and acetyltransferase activity. The present invention encompasses both native and recombinant wild-type forms of the transferase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type transferase. The present invention also relates to methods of using diacylglycerol acyltransferase genes and proteins, including in their expression in transgenic organisms and in the production of acetyl-glycerides in plant oils, and in particular seed oils.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV

DGAT genes and methods of use for triglyceride production in recombinant microorganisms

The present invention provides novel diacylglycerol acyltransferase (DGAT) genes, including novel genes encoding localization peptides. The present invention also provides recombinant cells, such as algae, transformed with DGAT genes and methods of using such recombinant cells to produce triglyceride.
Owner:EXXON RES & ENG CO

Diacylglycerol acyltransferase gene from plants

The present invention relates to the isolation, purification, characterization and use of the plant diacylglycerol acyltransferase (DGAT) gene and genetic products. The invention includes isolated and purified DGAT DNA and relates to methods of regulating seed oil content, the ratio of diacylglycerol / triacylglycerol proportions in the seed oil, fatty acid synthesis, seed oil acyl composition, seed size / weight and carbon flux into other seed components, using the gene, and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of the invention, and a method of producing such plants and plant seeds.
Owner:NAT RES COUNCIL OF CANADA

Recombinant microbial cells that produce at least 28% eicosapentaenoic acid as dry cell weight

ActiveUS20140186906A1Reduce the amount presentDecreases the total amount of sugar alcoholsFungiAcyltransferasesPhosphatidic acidPolynucleotide
Recombinant microbial cells are disclosed herein that produce an oil comprising at least 28 percent eicosapentaenoic acid (EPA) measured as a weight percent of dry cell weight. These cells may comprise a polynucleotide sequence encoding an active acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT) comprising at least one amino acid mutation in a membrane-bound O-acyltransferase motif. In addition, the cells may comprise a down-regulation of an endogenous polynucleotide sequence encoding Sou2 sorbitol utilization protein, and / or one or more polynucleotides encoding phospholipid:diacylglycerol acyltransferase (PDAT), delta-12 desaturase, a dihomo-gamma-linolenic acid (DGLA) synthase multizyme, delta-8 desaturase, malonyl-CoA synthetase (MCS), or acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT). Also disclosed are methods of using the recombinant microbial cells to produce oil containing omega-3 polyunsaturated fatty acids such as EPA.
Owner:DUPONT US HLDG LLC

Diacylglycerol acyltransferase genes, proteins, and uses thereof

The present invention relates to diacylglycerol acyltransferase genes and proteins, and methods of their use. In particular, the invention describes genes and proteins that exhibit both long-chain acyltransferase and acetyltransferase activity. The present invention encompasses both native and recombinant wild-type forms of the transferase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type transferase. The present invention also relates to methods of using diacylglycerol acyltransferase genes and proteins, including in their expression in transgenic organisms and in the production of acetyl-glycerides in plant oils, and in particular seed oils.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.
Owner:GLAXO SMITHKLINE LLC

Enzyme Directed Oil Biosynthesis In Microalgae

The present invention is related to biosynthetic oil compositions and methods of making thereof. In some embodiments, the invention relates to the use of endogenous enzymes in plants capable of synthesizing oil. In preferred embodiments, said plants are algae. In further embodiments, said algae are from the family Chlamydomonas, Nannochloropsis, Dunaliella, Chlorella and Scenedesmus. In still further embodiments, said endogenous enzymes are diacylglycerol acyltransferases.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV

CeDGAT1 (Chlorella ellipsoidea Diacylglycerol Acyltransferase 1) gene and application thereof

The invention provides a CeDGAT1 (Chlorella ellipsoidea Diacylglycerol Acyltransferase 1) gene and an application thereof for increasing the fatty acid content of cells. A nucleotide sequence of the CeDGAT1 is as shown in SEQ ID NO: 1. The CeDGAT1 gene is derived from Chlorella ellipsoidea, and encoded diacylglycerol acyltransferase is a key enzyme in the TAG (triacylglycerol) synthesis process in a biological body. The CeDGAT1 gene can be used for transforming yeast cells, plant cells and microalgae cells, so that the total fatty acid content of the cells can be greatly increased.
Owner:INST OF GENETICS & DEVELOPMENTAL BIOLOGY CHINESE ACAD OF SCI

Marker assisted selection of bovine for improved milk production using diacylglycerol acyltransferase gene DGAT1

The present invention provides a method of genotyping bovine for improved milk production traits by determining the DGAT1 genotypic state of said bovine, wherein the DGAT1 gene and polymorphisms within said gene have been found to be associated with such improved milk production traits.
Owner:NEOGEN CORP

Modified photosynthetic microorganisms for producing triglycerides

This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacylglycerol acyltransferase, a phosphatidate phosphatase, and / or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and / or synthesizing triglycerides.
Owner:LUMEN BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products